Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-10
2011-05-10
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S331000, C564S164000, C564S166000
Reexamination Certificate
active
07939541
ABSTRACT:
This invention relates to a process for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula (I)) starting from 4-methyl-2-nitro-aniline (formula (II)) through intermediates (3-trifluoromethylsulfonyl)-N-[4-methyl-3-nitrophenyl]-benzamide (formula (III)), (3-trifluoromethylsulfonyl)-N-[3-amino-4-methylphenyl]-benzamide (formula (IV)) and (3-trifluoromethylsulfonyl)-N-[3-guanidino-4-methylphenyl]-benzamide (formula (V)). This invention also relates to processes for the preparation of these intermediates. The compound of formula (I), also known as AN-024, is:
REFERENCES:
patent: 0 564 409 (1993-10-01), None
patent: WO 95/09847 (1995-04-01), None
patent: WO 99/15164 (1999-04-01), None
patent: WO 02/22597 (2002-03-01), None
patent: WO 2004/029038 (2004-04-01), None
patent: WO 2004/110452 (2004-12-01), None
patent: WO 2006/027795 (2006-03-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Gura, Systems for identifying New Drugs Are Often Faulty, Cancer Models, Science, vol. 278, No. 5340, pp. 1041-1042, Nov. 2007.
Johnson et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, British Journal of Cancer (2001) 64(10): 1424-1431.
Invitation to Pay Additional Fees with Partial International Search mailed Jul. 15, 2009.
Ogata et al. “Synthesis and Antiviral activity of sulphonamidobenzophenone oximes and sulphonamidobenzamides.”Journal of Medicinal Chemistry. vol. 29, No. 3. 1986. pp. 417-423.
Zimmermann et al. “Potent and selective inhibitors of the Abl-kinase: Phenylaminopyrimidine (PAP) derivatives.”Bioorganic and Medicinal Chemistry Letters. vol. 7, No. 2. 1997. pp. 187-192.
Schindler et al. “Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase.”Science. vol. 289, No. 5486. 2000. pp. 1938-1942.
Examination Report from corresponding European Application No. 05 779 775.5-2101 dated Feb. 16, 2010.
Examination Report from corresponding European Application No. 05 779 775.5-2101 dated Apr. 25, 2008.
Adibhatla Kali Satya Bhujanga rao
Kompella Amala kishan
Rachakonda Sreenivas
Venkaiah Chowdary Nannapaneni
Merchant & Gould P.C.
Natco Pharma Limited
Rao Deepak
LandOfFree
Intermediates and a process employing the intermediates for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intermediates and a process employing the intermediates for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intermediates and a process employing the intermediates for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682354